Compounding pharmacies in Pennsylvania
By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed. Last verified
The Pennsylvania State Board of Pharmacy (Department of State, Bureau of Professional and Occupational Affairs) regulates compounding pharmacies in Pennsylvania. Compounded GLP-1 limited. How to check a pharmacy's license, plus listings with their verification status.
Pennsylvania at a glance
- Pharmacy regulator
- Pennsylvania State Board of Pharmacy (Department of State, Bureau of Professional and Occupational Affairs)
- 503A framework
- Follows the federal 503A framework
- Telehealth prescribing
- Regulatory: Telehealth allowed
- Asynchronous prescribing
- Regulatory: Async unclear
- Compounded GLP-1 access
- Regulatory: Compounded GLP-1 limited
Compounding pharmacies serving Pennsylvania
No verified compounding pharmacies serving Pennsylvania are listed yet. A provider appears here only after it passes the verification checklist, and those checks are still under way.
Looking for care now? Start with what the law allows where you live, then how a legitimate prescription works.
Run a pharmacy, clinic, or telehealth service? Apply for a listing.
Who regulates compounding pharmacies in Pennsylvania
The State Board of Pharmacy licenses pharmacies under the Pharmacy Act (63 P.S. section 390-1 and following) and regulates practice through 49 Pa. Code chapter 27. The compounding rules at 49 Pa. Code sections 27.601 to 27.606 (effective June 22, 2019) require sterile and non-sterile compounding to follow section 503A of the federal Food, Drug, and Cosmetic Act, its regulations, and the current USP compounding chapters; section 27.602 bars pharmacists from compounding drugs FDA has withdrawn for safety or effectiveness, essentially copies of commercially available drugs except as 503A allows, and drugs FDA has identified as not compoundable. Pennsylvania has not adopted a separate list of compoundable bulk substances, so a peptide's eligibility follows the federal 503A test (approved drug component, USP or NF monograph, or FDA 503A bulks list). Section 4.1 of the Pharmacy Act (63 P.S. section 390-4.1, added in 2015) requires a nonresident pharmacy to register with the Board every two years, hold a valid home-state license, submit its most recent home-state or national inspection report, and provide a toll-free pharmacist line, and it bars shipping legend drugs into Pennsylvania without that certificate of registration. The Board's license verification confirms registration. [1] [2] [3] [5]
Compounded GLP-1 access in Pennsylvania
Telehealth GLP-1 patients should confirm the dispensing pharmacy holds a Pennsylvania pharmacy permit or nonresident pharmacy registration. [1] [8]
Research use only sellers in Pennsylvania
The Pennsylvania Pharmacy Act restricts dispensing of prescription drugs to licensed pharmacies, and the Controlled Substance, Drug, Device and Cosmetic Act (35 P.S. section 780-101 and following) prohibits the sale of adulterated, misbranded, or unapproved new drugs in the Commonwealth. [2] [4] [9]
How to check a compounding pharmacy in Pennsylvania
- Search the Pennsylvania State Board of Pharmacy (Department of State, Bureau of Professional and Occupational Affairs) license lookup for the pharmacy by name. A pharmacy based elsewhere needs whatever license or registration Pennsylvania requires before it ships to you. [1] [2] [3] [5]
- Ask whether it operates as a 503A pharmacy or a 503B outsourcing facility, and confirm a 503B claim against FDA's outsourcing facility information (see the verification checklist).
- Confirm the peptide can be lawfully compounded: check its status on the regulatory tracker or its peptide page before paying.
- Walk away from any seller that labels a peptide "research use only" or "not for human consumption". See the research use only section above for what that means in Pennsylvania. [2] [4] [9]
Common questions in Pennsylvania
Can an out-of-state pharmacy ship compounded peptides to me in Pennsylvania?
Only if it holds a certificate of registration from the Pennsylvania State Board of Pharmacy as a nonresident pharmacy. Section 4.1 of the Pharmacy Act (63 P.S. section 390-4.1) bars a nonresident pharmacy from shipping legend drugs into Pennsylvania without one. Search the Department of State license verification for the pharmacy name; if it is not registered, the shipment is not lawful in Pennsylvania even if the prescriber is compliant. [1] [2]
Can a Pennsylvania pharmacy compound BPC-157 or other unapproved peptides?
Only under a draft federal policy, and only within strict limits. On October 28, 2026 HHS released a draft enforcement discretion policy saying it will not take enforcement action against a state-licensed pharmacy that compounds BPC-157 as a single-ingredient product by an allowed route, on a patient-specific prescription, from an FDA-registered manufacturer's substance with a tested certificate of analysis, with serious adverse events reported to FDA. BPC-157 is still not FDA approved or on the 503A bulks list, the policy is not binding and HHS may revisit it, and blends such as Wolverine are not covered. FDA's drug center recommended against listing BPC-157; the advisory committee voted in favor (HHS policy, Appendix B). The draft covers only six single peptides (BPC-157, epitalon, KPV, MOTS-c, semax, TB-500); others, such as CJC-1295 and ipamorelin, are not covered. State law still applies: Pennsylvania has not adopted a separate list of compoundable bulk substances, so a peptide's eligibility follows the federal 503A test. [3] [6] [7] [10] [11]
Sources
- [1]Pennsylvania State Board of Pharmacy
- [2]Pennsylvania Pharmacy Act, Act of Sept. 27, 1961, P.L. 1700, No. 699 (63 P.S. section 390-1 and following), including section 4.1, Nonresident pharmacies
- [3]49 Pa. Code chapter 27, State Board of Pharmacy regulations (compounding, sections 27.601 to 27.606)
- [4]Pennsylvania Controlled Substance, Drug, Device and Cosmetic Act, 35 P.S. section 780-101 and following (Act 1972-64)
- [5]FDA: Section 503A of the Federal Food, Drug, and Cosmetic ActFDA
- [6]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (503A and 503B category lists)FDA
- [7]FDA: Pharmacy Compounding Advisory CommitteeFDA
- [8]FDA: concerns with unapproved GLP-1 drugs used for weight loss, including shortage resolution and compounding grace periodsFDA
- [9]21 U.S.C. 331, Prohibited acts
- [10]Federal Register notice of availability: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, FR Doc. 2026-22192 (Docket HHS-OASH-2026-0496)Federal Register, 2026
- [11]HHS: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (draft, with Appendix A and Appendix B)2026